Author

Thomas Podsadecki 1

1 AbbVie

SUSTAINED VIROLOGIC RESPONSE 12 WEEKS POST-TREATMENT WITH INTERFERON-FREE REGIMENS OF ABT-450/R, ABT-267, ABT-333, AND RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 DIFFICULT-TO-TREAT PATIENT SUBGROUPS

Maribel Rodriguez-Torres, Frederick Nunes, Daniel E. Cohen, Christal Marincic, Amit Khatri, Tami Pilot-Matias, Thomas Podsadecki, Barry Bernstein

SVR12 OF 99% ACHIEVED WITH A RIBAVIRIN-FREE REGIMEN OF ABT-450/R/OMBITASVIR AND DASABUVIR IN HCV GENOTYPE 1B-INFECTED PATIENTS

Andreas Maieron, Massimo Puoti, Jeffrey Enejosa, Ziv Ari, Gunnar Norkrans, Manuel Romero-Gomez, Daniel E. Cohen, Thomas Podsadecki

Item 1 - 2 / 2
1